<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00963820</url>
  </required_header>
  <id_info>
    <org_study_id>C16004</org_study_id>
    <secondary_id>U1111-1166-8401</secondary_id>
    <nct_id>NCT00963820</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma</brief_title>
  <official_title>An Open-Label, Dose-Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety profile, tolerability, and
      maximum tolerated dose of ixazomib citrate (MLN9708) when taken orally on a weekly dosing
      schedule by patients with relapsed and refractory multiple myeloma (RRMM). Secondary
      objectives include pharmacokinetics and response rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called ixazomib citrate (MLN9708). Ixazomib citrate is
      being tested for people who have multiple myeloma who have relapsed after treatment or become
      unresponsive to treatment.

      This study will determine the maximum tolerated dose (MTD) of ixazomib citrate using a dose
      escalation scheme. Once MTD is established, participants will be enrolled at MTD into one of
      the 4 expansion cohorts to characterize the safety, tolerability and efficacy of MLN9708.
      Blood samples for safety labs, hematology, serum chemistry and pharmacokinetic evaluations
      will be obtained at the timepoints specified. Disease response assessment is to be performed
      on the first day of every other cycle beginning with Cycle 3.

      The study will enroll approximately 60 patients. All participants will receive treatment with
      ixazomib citrate. This multi-center trial will be conducted in the United States. The overall
      time to participate in this study is up to 60 days, and participants will make 12-16 visits
      to the clinic for study procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-Emergent Adverse Events and Serious Adverse Events</measure>
    <time_frame>From the first dose through 30 days after last dose of ixazomib citrate or until the start of subsequent antineoplastic therapy (Up to 354 days)</time_frame>
    <description>An Adverse Event is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
A Serious Adverse Event (SAE) was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurotoxicity Grading</measure>
    <time_frame>Cycle 1 Day 1 and End of Study (Up to 354 days)</time_frame>
    <description>Neurotoxicity is graded using participant responses to 11 functional questions on a 5-point scale, where 0=Not at all and 4=Very much, using the Functional Assessment of Cancer Therapy/Gynecology Oncology Group - Neurotoxicity Questionnaire, Version 4.0(14). Neurotoxicity subscale is a sum of 11 reversed item scores where each original score is transformed as (4 - score). The highest possible score is 44, and a higher score indicates more neurotoxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for MLN2238</measure>
    <time_frame>Days 1 and 15 of Cycle 1</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for MLN2238</measure>
    <time_frame>Days 1 and 15 of Cycle 1</time_frame>
    <description>Tmax: Time to reach the maximum observed plasma concentration (Cmax), equal to time to Cmax. MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for MLN2238</measure>
    <time_frame>Days 1 and 15 of Cycle 1</time_frame>
    <description>AUC(0-168) is a measure of the area under the plasma concentration-time curve over the dosing interval (tau) (AUC[0-tau]), where tau is the length of the dosing interval - 168 hours in this study). MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio: Day 15 AUC0-168 / Day 1 AUC0-168 for MLN2238</measure>
    <time_frame>Day 15 of Cycle 1</time_frame>
    <description>MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Rate Constant (λz) for MLN2238</measure>
    <time_frame>Day 15 of Cycle 1</time_frame>
    <description>Terminal elimination rate constant (λz) is the rate at which drugs are eliminated from the body and the values were used for calculation of T1/2. MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Elimination Half-life (T1/2) for MLN2238</measure>
    <time_frame>Day 15 of Cycle 1</time_frame>
    <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma. MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emax: Maximum Inhibition</measure>
    <time_frame>Days 1 and 15 of Cycle 1</time_frame>
    <description>A Whole Blood 20S Proteasome Inhibition Parameter. There were no subjects in the Pharmacodynamic (PD) Analysis Set for the 2.23 mg/m^2 cohort, so PD tables do not include that arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEmax: Time of Occurrence of Emax</measure>
    <time_frame>Days 1 and 15 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response to Treatment With Ixazomib Citrate Based on Investigator's Evaluation Over Time</measure>
    <time_frame>Up to 354 days</time_frame>
    <description>Responses were based on International Myeloma Working Group Uniform Criteria. Complete Response (CR)=Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and &lt;5% plasma cells in bone marrow.
Partial Response (PR)= reduction in M-Protein ≥50% in serum and ≥90% in 24-hour urine. If M-protein unmeasurable, ≥50% decrease in difference of involved and uninvolved Free Light Chain (FLC). If M-protein and FLC unmeasurable, ≥50% reduction in plasma cells is required, if baseline bone marrow plasma cell ≥30%. And ≥50% reduction in the size of soft tissue plasmacytomas.
Minimal Response (MR)= 25-49% reduction in serum paraprotein for 6 weeks. 50-89% reduction in 24 hour urinary light chain excretion for 6 weeks. For Non-secretory myeloma patients, 25-49 % reduction in plasma cells in bone marrow and trephine biopsy for a 6 weeks. 25-49% reduction in the size of soft tissue plasmacytomas. No increase in the size or number of lytic bone lesions.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>0.24 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.48 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.80 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.20 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.68 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.23 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.97 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.95 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relapsed and Refractory (RR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib citrate, 2.97 mg/m^2 established Maximum Tolerated Dose (MTD), capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VELCADE-Relapsed (VR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PI naïve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carfilzomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixazomib citrate</intervention_name>
    <description>Ixazomib citrate capsules</description>
    <arm_group_label>0.24 mg/m^2</arm_group_label>
    <arm_group_label>0.48 mg/m^2</arm_group_label>
    <arm_group_label>0.80 mg/m^2</arm_group_label>
    <arm_group_label>1.20 mg/m^2</arm_group_label>
    <arm_group_label>1.68 mg/m^2</arm_group_label>
    <arm_group_label>2.23 mg/m^2</arm_group_label>
    <arm_group_label>2.97 mg/m^2</arm_group_label>
    <arm_group_label>3.95 mg/m^2</arm_group_label>
    <arm_group_label>Relapsed and Refractory (RR)</arm_group_label>
    <arm_group_label>VELCADE-Relapsed (VR)</arm_group_label>
    <arm_group_label>PI naïve</arm_group_label>
    <arm_group_label>Carfilzomib</arm_group_label>
    <other_name>MLN9708</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each patient must meet all of the following eligibility criteria to be enrolled in the
        study:

          -  Adult patients with multiple myeloma who have relapsed following at least 2 lines of
             therapy.

          -  Patients must have measurable disease.

          -  Appropriate functional status, including the recovery from the effects of prior
             antineoplastic therapy, and acceptable organ function as described in the protocol.

          -  Female patients who are post menopausal, surgically sterile, or agree to practice 2
             effective methods of contraception or abstain from heterosexual intercourse.

          -  Male patients who agree to practice effective barrier contraception or agree to
             abstain from heterosexual intercourse.

          -  Willing and able to give written informed consent.

          -  Suitable venous access for study-required blood sampling.

        Exclusion Criteria:

          -  Peripheral neuropathy that is greater or equal to Grade 2.

          -  Major surgery or, serious infections, or infections that required systemic antibiotic
             therapy within 14 days before the first dose of study drug.

          -  Life-threatening illness unrelated to cancer.

          -  Diarrhea that is greater than Grade 1 as outlined in the protocol

          -  Systemic antineoplastic or radiation therapy within 14 days or cytotoxic agents, or
             treatment with any investigational products within 21 days before the first dose of
             study treatment.

          -  Treatment with any investigational proteasome inhibitor.

          -  Systemic treatment with prohibited medications that are outlined in the protocol
             within 14 days of study treatment.

          -  Ongoing therapy with corticosteroids greater than 10mg of prednisone or its equivalent
             per day.

          -  Central nervous system involvement.

          -  Evidence of current uncontrolled cardiovascular conditions, including cardiac
             arrhythmias, congestive heart failure, angina, or myocardial infarction within the
             past 6 months.

          -  Known human immunodeficiency virus (HIV) positive, hepatitis B surface
             antigen-positive status, or known or suspected active hepatitis C infection.

          -  Serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to the protocol.

          -  Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral
             absorption of tolerance of IXAZOMIB including difficulty swallowing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic- Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James R. Berenson, MD, Inc</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill-Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2009</study_first_submitted>
  <study_first_submitted_qc>August 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2009</study_first_posted>
  <results_first_submitted>May 29, 2015</results_first_submitted>
  <results_first_submitted_qc>July 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2015</results_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed multiple myeloma</keyword>
  <keyword>Refractory multiple myeloma</keyword>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
    <mesh_term>Glycine</mesh_term>
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sixty (60) participants took part in the study at 6 investigative sites in the United States from 31 October 2009 to database lock on 28 February 2013.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of multiple myeloma (relapsed and/or refractory) were enrolled in the dose escalation phase to determine maximum tolerated dose (MTD). Once the MTD was established, participants were enrolled at the MTD into 1 of the 4 expansion cohorts.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.24 mg/m^2</title>
          <description>Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
        </group>
        <group group_id="P2">
          <title>0.48 mg/m^2</title>
          <description>Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
        </group>
        <group group_id="P3">
          <title>0.80 mg/m^2</title>
          <description>Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
        </group>
        <group group_id="P4">
          <title>1.20 mg/m^2</title>
          <description>Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
        </group>
        <group group_id="P5">
          <title>1.68 mg/m^2</title>
          <description>Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
        </group>
        <group group_id="P6">
          <title>2.23 mg/m^2</title>
          <description>Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
        </group>
        <group group_id="P7">
          <title>2.97 mg/m^2</title>
          <description>Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
        </group>
        <group group_id="P8">
          <title>3.95 mg/m^2</title>
          <description>Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
        </group>
        <group group_id="P9">
          <title>Relapsed and Refractory (RR)</title>
          <description>Ixazomib citrate, 2.97 mg/m^2 established Maximum Tolerated Dose (MTD), capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort that includes 2 participants from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
        </group>
        <group group_id="P10">
          <title>VELCADE-relapsed (VR)</title>
          <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort that includes 1 participant from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
        </group>
        <group group_id="P11">
          <title>PI naïve</title>
          <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
        </group>
        <group group_id="P12">
          <title>Carfilzomib</title>
          <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Dose Escalation Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="0">Expansion cohorts were not part of Dose Escalation except as noted in comments.</participants>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Therapeutic Response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Expansion Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Dose escalation cohorts were not part of the Expansion Phase except as noted in comments.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="11">Includes 2 participants from the dose escalation cohort 2.97 mg/m^2.</participants>
                <participants group_id="P10" count="10">Includes 1 participant from the dose escalation cohort 2.97 mg/m^2.</participants>
                <participants group_id="P11" count="6">Includes only participants who are proteasome inhibitor (PI)-naïve.</participants>
                <participants group_id="P12" count="4">Includes participants with last dose of carfilzomib 21 to 60 days before 1st ixazomib citrate dose.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1">Participant was ongoing at the time of data cut off for analysis</participants>
                <participants group_id="P10" count="1">Participant was ongoing at the time of data cut off for analysis</participants>
                <participants group_id="P11" count="1">Participant was ongoing at the time of data cut off for analysis</participants>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Therapeutic Response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Safety Population</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.0" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <description>Height data was missing for 1 participant. Mean and standard deviation calculation is based on 59 participants.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.4" spread="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.26" spread="18.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area at Baseline</title>
          <description>Body Surface Area (BSA) was missing for 1 participant. Mean and standard deviation are based on 59 participants.</description>
          <units>m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.96" spread="0.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting One or More Treatment-Emergent Adverse Events and Serious Adverse Events</title>
        <description>An Adverse Event is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
A Serious Adverse Event (SAE) was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.</description>
        <time_frame>From the first dose through 30 days after last dose of ixazomib citrate or until the start of subsequent antineoplastic therapy (Up to 354 days)</time_frame>
        <population>Safety Population included all randomized participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>0.24 mg/m^2</title>
            <description>Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O2">
            <title>0.48 mg/m^2</title>
            <description>Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O3">
            <title>0.80 mg/m^2</title>
            <description>Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O4">
            <title>1.20 mg/m^2</title>
            <description>Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O5">
            <title>1.68 mg/m^2</title>
            <description>Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O6">
            <title>2.23 mg/m^2</title>
            <description>Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O7">
            <title>2.97 mg/m^2</title>
            <description>Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O8">
            <title>3.95 mg/m^2</title>
            <description>Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O9">
            <title>Relapsed and Refractory (RR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort that includes 2 participants from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O10">
            <title>VELCADE-relapsed (VR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort that includes 1 participant from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O11">
            <title>PI naïve</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O12">
            <title>Carfilzomib</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting One or More Treatment-Emergent Adverse Events and Serious Adverse Events</title>
          <description>An Adverse Event is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
A Serious Adverse Event (SAE) was any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.</description>
          <population>Safety Population included all randomized participants who received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="11"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="10"/>
                    <measurement group_id="O11" value="6"/>
                    <measurement group_id="O12" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for MLN2238</title>
        <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
        <time_frame>Days 1 and 15 of Cycle 1</time_frame>
        <population>Participants from the Pharmacokinetic (PK) Analysis Population, all participants who had sufficient dosing data to calculate PK parameters, with data available for calculation of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>0.24 mg/m^2</title>
            <description>Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O2">
            <title>0.48 mg/m^2</title>
            <description>Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O3">
            <title>0.80 mg/m^2</title>
            <description>Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O4">
            <title>1.20 mg/m^2</title>
            <description>Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O5">
            <title>1.68 mg/m^2</title>
            <description>Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O6">
            <title>2.23 mg/m^2</title>
            <description>Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O7">
            <title>2.97 mg/m^2</title>
            <description>Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O8">
            <title>3.95 mg/m^2</title>
            <description>Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O9">
            <title>Relapsed and Refractory (RR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort that includes 2 participants from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O10">
            <title>VELCADE-relapsed (VR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort that includes 1 participant from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O11">
            <title>PI naïve</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O12">
            <title>Carfilzomib</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for MLN2238</title>
          <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
          <population>Participants from the Pharmacokinetic (PK) Analysis Population, all participants who had sufficient dosing data to calculate PK parameters, with data available for calculation of Cmax.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1 (n=1,1,2,1,3,2,5,4,5,8,5,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.010">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O2" value="2.91">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="5.75" spread="4.1083"/>
                    <measurement group_id="O4" value="15.10">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="13.83" spread="9.7070"/>
                    <measurement group_id="O6" value="29.05" spread="11.1016"/>
                    <measurement group_id="O7" value="65.46" spread="29.3351"/>
                    <measurement group_id="O8" value="123.95" spread="79.2137"/>
                    <measurement group_id="O9" value="75.92" spread="30.3995"/>
                    <measurement group_id="O10" value="110.43" spread="62.7006"/>
                    <measurement group_id="O11" value="77.70" spread="37.9107"/>
                    <measurement group_id="O12" value="83.73" spread="87.8161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 15 (n=3,1,3,2,2,1,2,1,5,5,4,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="0.9616"/>
                    <measurement group_id="O2" value="4.64">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O3" value="6.89" spread="5.1116"/>
                    <measurement group_id="O4" value="17.90" spread="8.6267"/>
                    <measurement group_id="O5" value="17.63" spread="12.6926"/>
                    <measurement group_id="O6" value="9.24">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O7" value="100.55" spread="15.1339"/>
                    <measurement group_id="O8" value="134.00">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O9" value="50.46" spread="22.6877"/>
                    <measurement group_id="O10" value="93.68" spread="52.7617"/>
                    <measurement group_id="O11" value="118.05" spread="54.2907"/>
                    <measurement group_id="O12" value="55.10" spread="41.5275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for MLN2238</title>
        <description>Tmax: Time to reach the maximum observed plasma concentration (Cmax), equal to time to Cmax. MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
        <time_frame>Days 1 and 15 of Cycle 1</time_frame>
        <population>Participants from the PK Analysis Population, all participants who had sufficient dosing data to calculate PK parameters, with data available for analysis of Tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>0.24 mg/m^2</title>
            <description>Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O2">
            <title>0.48 mg/m^2</title>
            <description>Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O3">
            <title>0.80 mg/m^2</title>
            <description>Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O4">
            <title>1.20 mg/m^2</title>
            <description>Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O5">
            <title>1.68 mg/m^2</title>
            <description>Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O6">
            <title>2.23 mg/m^2</title>
            <description>Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O7">
            <title>2.97 mg/m^2</title>
            <description>Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O8">
            <title>3.95 mg/m^2</title>
            <description>Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O9">
            <title>Relapsed and Refractory (RR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort that includes 2 participants from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O10">
            <title>VELCADE-relapsed (VR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort that includes 1 participant from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O11">
            <title>PI naïve</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O12">
            <title>Carfilzomib</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for MLN2238</title>
          <description>Tmax: Time to reach the maximum observed plasma concentration (Cmax), equal to time to Cmax. MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
          <population>Participants from the PK Analysis Population, all participants who had sufficient dosing data to calculate PK parameters, with data available for analysis of Tmax.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1 (n=1,1,2,1,3,2,5,4,5,8,5,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.50" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.53" lower_limit="1.53" upper_limit="1.53"/>
                    <measurement group_id="O3" value="1.52" lower_limit="1.03" upper_limit="2.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O5" value="1.52" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O6" value="1.25" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O7" value="1.00" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O8" value="1.00" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O9" value="2.00" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O10" value="0.50" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O11" value="1.00" lower_limit="0.50" upper_limit="1.42"/>
                    <measurement group_id="O12" value="1.42" lower_limit="1.00" upper_limit="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 15 (n=3,1,3,2,2,1,2,1,5,5,4,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.50" upper_limit="0.50"/>
                    <measurement group_id="O3" value="1.83" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O5" value="1.27" lower_limit="1.00" upper_limit="1.53"/>
                    <measurement group_id="O6" value="8.00" lower_limit="8.00" upper_limit="8.00"/>
                    <measurement group_id="O7" value="1.25" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O8" value="1.03" lower_limit="1.03" upper_limit="1.03"/>
                    <measurement group_id="O9" value="1.50" lower_limit="1.00" upper_limit="4.03"/>
                    <measurement group_id="O10" value="1.00" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O11" value="1.00" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O12" value="1.03" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for MLN2238</title>
        <description>AUC(0-168) is a measure of the area under the plasma concentration-time curve over the dosing interval (tau) (AUC[0-tau]), where tau is the length of the dosing interval - 168 hours in this study). MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
        <time_frame>Days 1 and 15 of Cycle 1</time_frame>
        <population>Participants from the PK Analysis Population, all participants who had sufficient dosing data to calculate PK parameters, with data available for calculation of AUC(0-168).</population>
        <group_list>
          <group group_id="O1">
            <title>0.24 mg/m^2</title>
            <description>Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O2">
            <title>0.48 mg/m^2</title>
            <description>Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O3">
            <title>0.80 mg/m^2</title>
            <description>Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O4">
            <title>1.20 mg/m^2</title>
            <description>Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O5">
            <title>1.68 mg/m^2</title>
            <description>Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O6">
            <title>2.23 mg/m^2</title>
            <description>Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O7">
            <title>2.97 mg/m^2</title>
            <description>Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O8">
            <title>3.95 mg/m^2</title>
            <description>Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O9">
            <title>Relapsed and Refractory (RR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort that includes 2 participants from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O10">
            <title>VELCADE-relapsed (VR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort that includes 1 participant from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O11">
            <title>PI naïve</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O12">
            <title>Carfilzomib</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for MLN2238</title>
          <description>AUC(0-168) is a measure of the area under the plasma concentration-time curve over the dosing interval (tau) (AUC[0-tau]), where tau is the length of the dosing interval - 168 hours in this study). MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
          <population>Participants from the PK Analysis Population, all participants who had sufficient dosing data to calculate PK parameters, with data available for calculation of AUC(0-168).</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1 (n=0,0,0,0,2,1,3,4,3,5,4,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants with evaluable data</measurement>
                    <measurement group_id="O2" value="NA">No participants with evaluable data</measurement>
                    <measurement group_id="O3" value="NA">No participants with evaluable data</measurement>
                    <measurement group_id="O4" value="NA">No participants with evaluable data</measurement>
                    <measurement group_id="O5" value="258.00" spread="93.3381"/>
                    <measurement group_id="O6" value="598.00">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O7" value="1269.67" spread="429.3837"/>
                    <measurement group_id="O8" value="1371.25" spread="725.1939"/>
                    <measurement group_id="O9" value="1793.33" spread="507.6744"/>
                    <measurement group_id="O10" value="854.20" spread="330.0745"/>
                    <measurement group_id="O11" value="750.25" spread="312.3890"/>
                    <measurement group_id="O12" value="813.67" spread="262.5649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 15 (n=0,0,2,0,2,1,2,1,1,4,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants with evaluable data</measurement>
                    <measurement group_id="O2" value="NA">No participants with evaluable data</measurement>
                    <measurement group_id="O3" value="398.50" spread="45.9616"/>
                    <measurement group_id="O4" value="NA">No participants with evaluable data</measurement>
                    <measurement group_id="O5" value="663.00" spread="142.8356"/>
                    <measurement group_id="O6" value="868.00">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O7" value="3100.00" spread="834.3860"/>
                    <measurement group_id="O8" value="1460.00">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O9" value="3690.00">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O10" value="1777.75" spread="958.4767"/>
                    <measurement group_id="O11" value="1549.00" spread="1027.6930"/>
                    <measurement group_id="O12" value="2075.00" spread="1025.3048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratio: Day 15 AUC0-168 / Day 1 AUC0-168 for MLN2238</title>
        <description>MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
        <time_frame>Day 15 of Cycle 1</time_frame>
        <population>Participants from the PK Analysis Population, all participants who had sufficient dosing data to calculate PK parameters, with data available for calculation of accumulation ratio.</population>
        <group_list>
          <group group_id="O1">
            <title>0.24 mg/m^2</title>
            <description>Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O2">
            <title>0.48 mg/m^2</title>
            <description>Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O3">
            <title>0.80 mg/m^2</title>
            <description>Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O4">
            <title>1.20 mg/m^2</title>
            <description>Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O5">
            <title>1.68 mg/m^2</title>
            <description>Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O6">
            <title>2.23 mg/m^2</title>
            <description>Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O7">
            <title>2.97 mg/m^2</title>
            <description>Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O8">
            <title>3.95 mg/m^2</title>
            <description>Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O9">
            <title>Relapsed and Refractory (RR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort that includes 2 participants from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O10">
            <title>VELCADE-relapsed (VR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort that includes 1 participant from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O11">
            <title>PI naïve</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O12">
            <title>Carfilzomib</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio: Day 15 AUC0-168 / Day 1 AUC0-168 for MLN2238</title>
          <description>MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
          <population>Participants from the PK Analysis Population, all participants who had sufficient dosing data to calculate PK parameters, with data available for calculation of accumulation ratio.</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="2.64" spread="0.3960"/>
                    <measurement group_id="O6" value="1.45">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O7" value="2.25">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O8" value="1.19">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O9" value="2.25">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O10" value="2.19" spread="0.8228"/>
                    <measurement group_id="O11" value="1.97" spread="0.5869"/>
                    <measurement group_id="O12" value="2.37" spread="0.2192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Rate Constant (λz) for MLN2238</title>
        <description>Terminal elimination rate constant (λz) is the rate at which drugs are eliminated from the body and the values were used for calculation of T1/2. MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
        <time_frame>Day 15 of Cycle 1</time_frame>
        <population>Participants from the PK Analysis Population, all participants who had sufficient dosing data to calculate PK parameters, with data available for calculation of terminal elimination rate constant.</population>
        <group_list>
          <group group_id="O1">
            <title>0.24 mg/m^2</title>
            <description>Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O2">
            <title>0.48 mg/m^2</title>
            <description>Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O3">
            <title>0.80 mg/m^2</title>
            <description>Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O4">
            <title>1.20 mg/m^2</title>
            <description>Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O5">
            <title>1.68 mg/m^2</title>
            <description>Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O6">
            <title>2.23 mg/m^2</title>
            <description>Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O7">
            <title>2.97 mg/m^2</title>
            <description>Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O8">
            <title>3.95 mg/m^2</title>
            <description>Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O9">
            <title>Relapsed and Refractory (RR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort that includes 2 participants from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O10">
            <title>VELCADE-relapsed (VR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort that includes 1 participant from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O11">
            <title>PI naïve</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O12">
            <title>Carfilzomib</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Rate Constant (λz) for MLN2238</title>
          <description>Terminal elimination rate constant (λz) is the rate at which drugs are eliminated from the body and the values were used for calculation of T1/2. MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
          <population>Participants from the PK Analysis Population, all participants who had sufficient dosing data to calculate PK parameters, with data available for calculation of terminal elimination rate constant.</population>
          <units>1/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.000">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O4" value="0.000" spread="0.0001"/>
                    <measurement group_id="O5" value="0.000" spread="0.0003"/>
                    <measurement group_id="O6" value="0.00">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O7" value="0.00">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O8" value="0.00">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O9" value="0.00" spread="0.0019"/>
                    <measurement group_id="O10" value="0.00" spread="0.0014"/>
                    <measurement group_id="O11" value="0.01" spread="0.0019"/>
                    <measurement group_id="O12" value="0.01" spread="0.0003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Phase Elimination Half-life (T1/2) for MLN2238</title>
        <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma. MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
        <time_frame>Day 15 of Cycle 1</time_frame>
        <population>Participants from the PK Analysis Population, all participants who had sufficient dosing data to calculate PK parameters, with data available for calculation of terminal phase elimination half-life.</population>
        <group_list>
          <group group_id="O1">
            <title>0.24 mg/m^2</title>
            <description>Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O2">
            <title>0.48 mg/m^2</title>
            <description>Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O3">
            <title>0.80 mg/m^2</title>
            <description>Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O4">
            <title>1.20 mg/m^2</title>
            <description>Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O5">
            <title>1.68 mg/m^2</title>
            <description>Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O6">
            <title>2.23 mg/m^2</title>
            <description>Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O7">
            <title>2.97 mg/m^2</title>
            <description>Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O8">
            <title>3.95 mg/m^2</title>
            <description>Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O9">
            <title>Relapsed and Refractory (RR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort that includes 2 participants from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O10">
            <title>VELCADE-relapsed (VR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort that includes 1 participant from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O11">
            <title>PI naïve</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O12">
            <title>Carfilzomib</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Elimination Half-life (T1/2) for MLN2238</title>
          <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma. MLN2238 is the complete hydrolysis product of the study drug ixazomib citrate (MLN9708).</description>
          <population>Participants from the PK Analysis Population, all participants who had sufficient dosing data to calculate PK parameters, with data available for calculation of terminal phase elimination half-life.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="4"/>
                <count group_id="O12" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="271.00">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O4" value="190.50" spread="7.7782"/>
                    <measurement group_id="O5" value="189.00" spread="12.7279"/>
                    <measurement group_id="O6" value="175.00">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O7" value="246.00">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O8" value="165.00">Can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O9" value="186.00" spread="84.8528"/>
                    <measurement group_id="O10" value="202.33" spread="63.0899"/>
                    <measurement group_id="O11" value="123.90" spread="39.4620"/>
                    <measurement group_id="O12" value="108.00" spread="4.2426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emax: Maximum Inhibition</title>
        <description>A Whole Blood 20S Proteasome Inhibition Parameter. There were no subjects in the Pharmacodynamic (PD) Analysis Set for the 2.23 mg/m^2 cohort, so PD tables do not include that arm.</description>
        <time_frame>Days 1 and 15 of Cycle 1</time_frame>
        <population>PD analysis Population included all participants who had sufficient dosing data to calculate PD parameters</population>
        <group_list>
          <group group_id="O1">
            <title>0.24 mg/m^2</title>
            <description>Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O2">
            <title>0.48 mg/m^2</title>
            <description>Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O3">
            <title>0.80 mg/m^2</title>
            <description>Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O4">
            <title>1.20 mg/m^2</title>
            <description>Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O5">
            <title>1.68 mg/m^2</title>
            <description>Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O6">
            <title>2.23 mg/m^2</title>
            <description>Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O7">
            <title>2.97 mg/m^2</title>
            <description>Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O8">
            <title>3.95 mg/m^2</title>
            <description>Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O9">
            <title>Relapsed and Refractory (RR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort that includes 2 participants from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O10">
            <title>VELCADE-relapsed (VR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort that includes 1 participant from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O11">
            <title>PI naïve</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O12">
            <title>Carfilzomib</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Emax: Maximum Inhibition</title>
          <description>A Whole Blood 20S Proteasome Inhibition Parameter. There were no subjects in the Pharmacodynamic (PD) Analysis Set for the 2.23 mg/m^2 cohort, so PD tables do not include that arm.</description>
          <population>PD analysis Population included all participants who had sufficient dosing data to calculate PD parameters</population>
          <units>Percentage of inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="10"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported</measurement>
                    <measurement group_id="O2" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported</measurement>
                    <measurement group_id="O3" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported</measurement>
                    <measurement group_id="O4" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported</measurement>
                    <measurement group_id="O5" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported</measurement>
                    <measurement group_id="O6" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported</measurement>
                    <measurement group_id="O7" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported</measurement>
                    <measurement group_id="O8" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported</measurement>
                    <measurement group_id="O9" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported</measurement>
                    <measurement group_id="O10" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported</measurement>
                    <measurement group_id="O11" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported</measurement>
                    <measurement group_id="O12" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TEmax: Time of Occurrence of Emax</title>
        <time_frame>Days 1 and 15 of Cycle 1</time_frame>
        <population>PD analysis population included all participants who had sufficient dosing data to calculate PD parameters</population>
        <group_list>
          <group group_id="O1">
            <title>0.24 mg/m^2</title>
            <description>Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O2">
            <title>0.48 mg/m^2</title>
            <description>Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O3">
            <title>0.80 mg/m^2</title>
            <description>Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O4">
            <title>1.20 mg/m^2</title>
            <description>Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O5">
            <title>1.68 mg/m^2</title>
            <description>Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O6">
            <title>2.23 mg/m^2</title>
            <description>Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O7">
            <title>2.97 mg/m^2</title>
            <description>Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O8">
            <title>3.95 mg/m^2</title>
            <description>Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O9">
            <title>Relapsed and Refractory (RR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort that includes 2 participants from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O10">
            <title>VELCADE-relapsed (VR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort that includes 1 participant from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O11">
            <title>PI naïve</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O12">
            <title>Carfilzomib</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
        </group_list>
        <measure>
          <title>TEmax: Time of Occurrence of Emax</title>
          <population>PD analysis population included all participants who had sufficient dosing data to calculate PD parameters</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="10"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported.</measurement>
                    <measurement group_id="O2" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported.</measurement>
                    <measurement group_id="O3" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported.</measurement>
                    <measurement group_id="O4" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported.</measurement>
                    <measurement group_id="O5" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported.</measurement>
                    <measurement group_id="O6" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported.</measurement>
                    <measurement group_id="O7" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported.</measurement>
                    <measurement group_id="O8" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported.</measurement>
                    <measurement group_id="O9" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported.</measurement>
                    <measurement group_id="O10" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported.</measurement>
                    <measurement group_id="O11" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported.</measurement>
                    <measurement group_id="O12" value="NA">Due to concerns about the third-party laboratory’s performance of the 20S assay, accuracy of the data cannot be considered reliable, and therefore, is not being reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response to Treatment With Ixazomib Citrate Based on Investigator's Evaluation Over Time</title>
        <description>Responses were based on International Myeloma Working Group Uniform Criteria. Complete Response (CR)=Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and &lt;5% plasma cells in bone marrow.
Partial Response (PR)= reduction in M-Protein ≥50% in serum and ≥90% in 24-hour urine. If M-protein unmeasurable, ≥50% decrease in difference of involved and uninvolved Free Light Chain (FLC). If M-protein and FLC unmeasurable, ≥50% reduction in plasma cells is required, if baseline bone marrow plasma cell ≥30%. And ≥50% reduction in the size of soft tissue plasmacytomas.
Minimal Response (MR)= 25–49% reduction in serum paraprotein for 6 weeks. 50–89% reduction in 24 hour urinary light chain excretion for 6 weeks. For Non-secretory myeloma patients, 25–49 % reduction in plasma cells in bone marrow and trephine biopsy for a 6 weeks. 25–49% reduction in the size of soft tissue plasmacytomas. No increase in the size or number of lytic bone lesions.</description>
        <time_frame>Up to 354 days</time_frame>
        <population>Response-Evaluable Population included all participants who had measurable disease at Baseline, had received at least 1 dose of study drug, and had at least 1 post-baseline response assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>0.24 mg/m^2</title>
            <description>Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O2">
            <title>0.48 mg/m^2</title>
            <description>Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O3">
            <title>0.80 mg/m^2</title>
            <description>Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O4">
            <title>1.20 mg/m^2</title>
            <description>Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O5">
            <title>1.68 mg/m^2</title>
            <description>Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O6">
            <title>2.23 mg/m^2</title>
            <description>Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O7">
            <title>2.97 mg/m^2</title>
            <description>Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O8">
            <title>3.95 mg/m^2</title>
            <description>Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O9">
            <title>Relapsed and Refractory (RR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort that includes 2 participants from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O10">
            <title>VELCADE-relapsed (VR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort that includes 1 participant from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O11">
            <title>PI naïve</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O12">
            <title>Carfilzomib</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response to Treatment With Ixazomib Citrate Based on Investigator's Evaluation Over Time</title>
          <description>Responses were based on International Myeloma Working Group Uniform Criteria. Complete Response (CR)=Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and &lt;5% plasma cells in bone marrow.
Partial Response (PR)= reduction in M-Protein ≥50% in serum and ≥90% in 24-hour urine. If M-protein unmeasurable, ≥50% decrease in difference of involved and uninvolved Free Light Chain (FLC). If M-protein and FLC unmeasurable, ≥50% reduction in plasma cells is required, if baseline bone marrow plasma cell ≥30%. And ≥50% reduction in the size of soft tissue plasmacytomas.
Minimal Response (MR)= 25–49% reduction in serum paraprotein for 6 weeks. 50–89% reduction in 24 hour urinary light chain excretion for 6 weeks. For Non-secretory myeloma patients, 25–49 % reduction in plasma cells in bone marrow and trephine biopsy for a 6 weeks. 25–49% reduction in the size of soft tissue plasmacytomas. No increase in the size or number of lytic bone lesions.</description>
          <population>Response-Evaluable Population included all participants who had measurable disease at Baseline, had received at least 1 dose of study drug, and had at least 1 post-baseline response assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="11"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR + PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="25" lower_limit="0" upper_limit="81"/>
                    <measurement group_id="O8" value="25" lower_limit="0" upper_limit="81"/>
                    <measurement group_id="O9" value="9" lower_limit="0" upper_limit="41"/>
                    <measurement group_id="O10" value="22" lower_limit="3" upper_limit="60"/>
                    <measurement group_id="O11" value="17" lower_limit="0" upper_limit="64"/>
                    <measurement group_id="O12" value="25" lower_limit="0" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CR + PR + MR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="25" lower_limit="0" upper_limit="81"/>
                    <measurement group_id="O8" value="25" lower_limit="0" upper_limit="81"/>
                    <measurement group_id="O9" value="18" lower_limit="2" upper_limit="52"/>
                    <measurement group_id="O10" value="33" lower_limit="7" upper_limit="70"/>
                    <measurement group_id="O11" value="17" lower_limit="0" upper_limit="64"/>
                    <measurement group_id="O12" value="25" lower_limit="0" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Neurotoxicity Grading</title>
        <description>Neurotoxicity is graded using participant responses to 11 functional questions on a 5-point scale, where 0=Not at all and 4=Very much, using the Functional Assessment of Cancer Therapy/Gynecology Oncology Group - Neurotoxicity Questionnaire, Version 4.0(14). Neurotoxicity subscale is a sum of 11 reversed item scores where each original score is transformed as (4 - score). The highest possible score is 44, and a higher score indicates more neurotoxicity.</description>
        <time_frame>Cycle 1 Day 1 and End of Study (Up to 354 days)</time_frame>
        <population>Safety Population included all randomized participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>0.24 mg/m^2</title>
            <description>Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O2">
            <title>0.48 mg/m^2</title>
            <description>Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O3">
            <title>0.80 mg/m^2</title>
            <description>Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O4">
            <title>1.20 mg/m^2</title>
            <description>Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O5">
            <title>1.68 mg/m^2</title>
            <description>Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O6">
            <title>2.23 mg/m^2</title>
            <description>Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O7">
            <title>2.97 mg/m^2</title>
            <description>Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O8">
            <title>3.95 mg/m^2</title>
            <description>Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O9">
            <title>Relapsed and Refractory (RR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort that includes 2 participants from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O10">
            <title>VELCADE-relapsed (VR)</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort that includes 1 participant from the dose escalation cohort 2.97 mg/m^2. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O11">
            <title>PI naïve</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
          <group group_id="O12">
            <title>Carfilzomib</title>
            <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Neurotoxicity Grading</title>
          <description>Neurotoxicity is graded using participant responses to 11 functional questions on a 5-point scale, where 0=Not at all and 4=Very much, using the Functional Assessment of Cancer Therapy/Gynecology Oncology Group - Neurotoxicity Questionnaire, Version 4.0(14). Neurotoxicity subscale is a sum of 11 reversed item scores where each original score is transformed as (4 - score). The highest possible score is 44, and a higher score indicates more neurotoxicity.</description>
          <population>Safety Population included all randomized participants who received study drug.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="11"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1 (n=2,3,3,3,4,3,7,4,9,8,6,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.00" spread="9.899"/>
                    <measurement group_id="O2" value="40.33" spread="1.155"/>
                    <measurement group_id="O3" value="42.00" spread="3.464"/>
                    <measurement group_id="O4" value="36.00" spread="7.937"/>
                    <measurement group_id="O5" value="39.50" spread="2.646"/>
                    <measurement group_id="O6" value="36.80" spread="4.530"/>
                    <measurement group_id="O7" value="33.14" spread="7.841"/>
                    <measurement group_id="O8" value="38.50" spread="4.203"/>
                    <measurement group_id="O9" value="38.44" spread="5.053"/>
                    <measurement group_id="O10" value="33.73" spread="6.935"/>
                    <measurement group_id="O11" value="38.00" spread="6.928"/>
                    <measurement group_id="O12" value="32.00" spread="8.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (n=3,3,2,1,1,3,4,3,8,5,4,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" spread="3.606"/>
                    <measurement group_id="O2" value="40.67" spread="2.517"/>
                    <measurement group_id="O3" value="38.50" spread="3.536"/>
                    <measurement group_id="O4" value="35.00" spread="0.000"/>
                    <measurement group_id="O5" value="42.00" spread="0.000"/>
                    <measurement group_id="O6" value="36.00" spread="3.606"/>
                    <measurement group_id="O7" value="36.00" spread="7.528"/>
                    <measurement group_id="O8" value="33.33" spread="8.386"/>
                    <measurement group_id="O9" value="33.88" spread="9.219"/>
                    <measurement group_id="O10" value="27.24" spread="13.122"/>
                    <measurement group_id="O11" value="37.00" spread="5.944"/>
                    <measurement group_id="O12" value="27.33" spread="7.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose through 30 days after last dose of ixazomib citrate or until the start of subsequent antineoplastic therapy (Up to 354 days)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dose Escalation Cohorts</title>
          <description>Ixazomib citrate, 0.24 to 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Dose Escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
        </group>
        <group group_id="E2">
          <title>Expansion Cohorts</title>
          <description>Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Expansion Period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperviscosity syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Stenosis or Obstruction of Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abscess Neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator may publish clinical data after the earlier of publication by Sponsor or 12 months after early termination or database lock. Proposed publication copy should be provided to Sponsor at least 30 days prior to submission/disclosure. If requested, Sponsor's confidential information must be removed and publication delayed if Sponsor intends to file a related patent application.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

